HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”

BackgroundProprotein convertase subtilisin kexin 9 (PCSK9) inhibitors reduce low‐density lipoprotein cholesterol (LDL‐C) and improve outcomes in the general population. HIV‐infected individuals are at increased risk for cardiovascular events and have high rates of dyslipidemia and hepatitis C virus...

Full description

Bibliographic Details
Main Authors: Payal Kohli, Peter Ganz, Yifei Ma, Rebecca Scherzer, Sophia Hur, Bernard Weigel, Carl Grunfeld, Steven Deeks, Scott Wasserman, Rob Scott, Priscilla Y. Hsue
Format: Article
Language:English
Published: Wiley 2016-05-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
hepatitis C virus
HIV
low‐density lipoprotein cholesterol
proprotein convertase subtilisin kexin 9
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.115.002683

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.115.002683

Similar Items